Who is sponsoring NCT04531033?

NCT04531033 is sponsored by Lemuel W. Taylor IV.

What drugs are being tested in NCT04531033?

Interventions in NCT04531033: Lactobacillus acidophilus MPH734, Placebo.

What condition does NCT04531033 study?

NCT04531033 studies Lactose Intolerance.

Is NCT04531033 still recruiting?

NCT04531033 is currently completed. Last updated 16 May 2024.

Last reviewed 2024-05-16 · How we verify

NCT04531033: LF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Does Daily Supplementation of Lactobacillus Acidophilus MPH734, for One Week, Affect Acute (Immediate), Subacute (7 Days), and Post-treatment Discontinuation Lactose Metabolism, Gastrointestinal Symptoms, and Clinical Markers of Inflammation and Safety Compared to a Placebo

Completed NA Last updated 16 May 2024

What this trial tests

NA trial testing Lactobacillus acidophilus MPH734 in Lactose Intolerance in 50 participants. Completed in 14 November 2022.

Timeline

25 August 2020

Primary endpoint
25 August 2021

14 November 2022

Quick facts

Lead sponsor	Lemuel W. Taylor IV
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	50
Start date	25 August 2020
Primary completion	25 August 2021
Estimated completion	14 November 2022
Sites	1 location across United States

Drugs / interventions tested

Lactobacillus acidophilus MPH734
Placebo

Conditions studied

Lactose Intolerance — all drugs for Lactose Intolerance →

Sponsor

Lemuel W. Taylor IV

Who can join

Adults 18 to 55, any sex, with Lactose Intolerance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine if twice or three times daily supplementation of Lactobacillus acidophilus MPH734 (Lacto-FreedomTM, or LF), for one week, affects acute (immediate), subacute (7 days), and post-treatment discontinuation (30-, 60-, and 90- day) lactose metabolism, gastrointestinal symptoms, and clinical markers of inflammation and safety compared to a placebo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04531033 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lemuel W. Taylor IV
Last refreshed: 16 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04531033.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing